Back to Search

NeoTAILOR: A Phase II Biomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

  • Protocol Number: 202305007
  • Principal Investigator: Bagegni, Nusayba
  • Cancer Types: Breast

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This study aims to utilize a novel biomarker-driven approach to guide neoadjuvant treatment selection. It is the hypothesis that this will improve clinical response for postmenopausal women with clinical stage II/III ER-positive, HER2-negative breast cancer and identify those who may not require neoadjuvant chemotherapy, with a primary focus on outcomes in Black patients.

Protocol Interventions

Device: VENTANA MIB-1 Ki67 assay, Device: Oncotype DX® Recurrence Score, Device: PAM50-based Prosigna breast cancer gene signature assay, Drug: Combination anthracycline and/or taxane based treatment